Help advance psychedelic research: PsyPal trial of psilocybin therapy in palliative care is recruiting across Europe
Psilocybin Therapy for Psychological Distress in Palliative Care Patients (PsyPal) - the first EU-funded clinical trial of psychedelic therapy - is now underway and actively recruiting participants across its four trial sites in Copenhagen, Groningen, Lisbon and Prague.
The study explores whether psilocybin therapy can help relieve psychological distress in people living with the following chronic and life-limiting conditions: chronic obstructive pulmonary disease, amyotrophic lateral sclerosis, multiple sclerosis, and atypical Parkinson’s disease.
Psilocybin therapy has shown promise in alleviating depression and enhancing well-being. The trial will assess whether it could offer meaningful relief and improve quality of life for people living with these conditions, where existing palliative care options fall short.
If you or someone you know might be eligible and interested in participating, please get in touch with one of the sites’ medical specialists:
NL: Huib Kerstjens, h.a.m.kerstjens@umcg.nl
PT: Marcelo Mendonça, marcelo.mendonca@neuro.fchampalimaud.org
DK: Kirsten Svenstrup, kirsten.svenstrup@regionh.dk
CZ: Michal Zido, michal.zado@fnkv.cz or infopsypal@nudz.cz
For more information visit the official PsyPal website.
